Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › durvalumab

durvalumab

16 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of durvalumab

74 trials tracked of durvalumab: 10 in phase 3 or 4 and 4 with published results. The most-cited published study has 200 citations.

74Trials tracked
10Phase 3 & 4
0Recruiting
4With published results
Phase distribution
Phase 4 2 Phase 3 8 Phase 2 54 Phase 1 7 Other / NA 3
  1. Phase 3 Study of Durvalumab With Chemoradiotherapy for Women With Locally Advanced Cervical Cancer (CALLA) Completed · 200 cited
  2. Phase 3 Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin Completed · 53 cited
  3. Phase 3 A Study of Nivolumab and Ipilimumab in Untreated Participants With Stage 3 Non-small Cell Lung Cancer (NSCLC) That is Unable or Not Planned to be Removed by Surgery Completed · 41 cited
  4. Phase 3 Durvalumab Plus Chemotherapy in Untreated Patients With Extensive-Stage Small Cell Lung Cancer Completed · 1 cited
  5. Phase 4 Durvalumab Long-Term Safety and Efficacy Study Completed
  6. Phase 4 Study to Access Safety of Durvalumab in Indian Adult Patients With Locally Advanced NSCLC Completed
Show 44 more trials
  1. Phase 3 Lung-MAP: Durvalumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers Completed
  2. Phase 3 Phase III Study to Determine Efficacy of Durvalumab in Stage II-III Non-small Cell Lung Cancer (NSCLC) After Curative Intent Therapy. Completed
  3. Phase 3 Study of Durvalumab in Combination With Platinum and Etoposide for the First Line Treatment of Patients With Extensive-stage Small Cell Lung Cancer Completed
  4. Phase 3 A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC) Completed
  5. Phase 2 Neoadjuvant Durvalumab Alone or in Combination With Novel Agents in Resectable Non-Small Cell Lung Cancer Completed
  6. Phase 2 A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers Completed
  7. Phase 2 Study of Durvalumab and Tremelimumab After Radiation for Microsatellite Stable Metastatic Colorectal Cancer Progressing on Chemotherapy Completed
  8. Phase 2 Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRCA2 Mutation Completed
  9. Phase 2 Phase II MEDI4736 in Combination With Chemotherapy for First-Line Treatment of Unresectable Mesothelioma Completed
  10. Phase 2 A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC) Completed
  11. Phase 2 Durvalumab (MEDI4736) With Cetuximab in Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Completed
  12. Phase 2 A Phase 1/2, Open-label Study to Evaluate the Safety and Antitumor Activity of MEDI0680 (AMP-514) in Combination With Durvalumab Versus Nivolumab Monotherapy in Participants With Select Advanced Malignancies Completed
  13. Phase 2 Phase 1/2 Study of Ensartinib and Durvalumab, in ALK-rearranged Non-small Cell Lung Cancer Completed
  14. Phase 2 Study of Durvalumab Following Radiation Therapy in Patients With Stage 3 Unresectable NSCLC Ineligible for Chemotherapy Completed
  15. Phase 2 TPIV200/huFR-1 (A Multi-Epitope Anti-Folate Receptor Vaccine) Plus Anti-PD-L1 MEDI4736 (Durvalumab) in Patients With Platinum Resistant Ovarian Cancer Completed
  16. Phase 2 A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies Completed
  17. Phase 2 Durvalumab With or Without Tremelimumab in Metastatic Castration Resistant Prostate Cancer Completed
  18. Phase 2 A Study to Determine Safety of Durvalumab After Sequential Chemo Radiation in Patients With Unresectable Stage III Non-Small Cell Lung Cancer Completed
  19. Phase 2 Durvalumab (MEDI4736) Plus Tremelimumab for Advanced Neuroendocrine Neoplasms of Gastroenteropancreatic or Lung Origin Completed
  20. Phase 2 Durvalumab and SNDX-6532 Following Chemo or Radio-Embolization for Patients With Intrahepatic Cholangiocarcinoma Completed
  21. Phase 2 Gemcitabine and Nab-Paclitaxel vs Gemcitabine, Nab-Paclitaxel, Durvalumab and Tremelimumab as 1st Line Therapy in Metastatic Pancreatic Adenocarcinoma Completed
  22. Phase 2 A Study to Determine the Efficacy of the Combination of Daratumumab (DARA) Plus Durvalumab (DURVA) (D2) in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) Completed
  23. Phase 2 Immune Checkpoint Inhibition (Tremelimumab and/or MEDI4736) in Combination With Radiation Therapy in Patients With Unresectable Pancreatic Cancer Completed
  24. Phase 2 Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Oesophageal Cancer Completed
  25. Phase 2 A Study of Durvalumab (MEDI4736) in Esophageal Cancer Completed
  26. Phase 2 A Study of Durvalumab With or Without Tremelimumab in Endometrial Cancer Completed
  27. Phase 2 An Open-label, Phase II Study of AZD4635 in Patients With Prostate Cancer Completed
  28. Phase 2 Durvalumab and Tremelimumab in Patients With Advanced Rare Tumours Completed
  29. Phase 2 A Study of AZD4635 With Durvalumab and With Cabazitaxel and Durvalumab in Patients With mCRPC. Completed
  30. Phase 2 Phase 1/2 Study of Combination Immunotherapy and Messenger Ribonucleic Acid (mRNA) Vaccine in Subjects With NSCLC Completed
  31. Phase 2 Safety and Efficacy of MEDI0457 and Durvalumab in Participants With Human Papilloma Virus (HPV) Associated Recurrent/Metastatic Head and Neck Cancer Completed
  32. Phase 2 Hepatic Artery Infusion Chemotherapy (HAIC) Plus Durvalumab for Advanced Hepatocellular Carcinoma Completed
  33. Phase 2 Durvalumab and Tremelimumab and Best Supportive Care vs Best Supportive Care in Patients With Advanced Colorectal Cancer Completed
  34. Phase 2 A Study of Durvalumab in Combination With Lenalidomide With and Without Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma Completed
  35. Phase 2 A Phase I/II Study of Pexa-Vec Oncolytic Virus in Combination With Immune Checkpoint Inhibition in Refractory Colorectal Cancer Completed
  36. Phase 2 Durvalumab in HIV-1 Patients With Solid Tumors Completed
  37. Phase 2 Multi-Arm Study to Test the Efficacy of Immunotherapeutic Agents in Multiple Sarcoma Subtypes Completed
  38. Phase 2 Durvalumab (MEDI4736) With or Without SBRT in Clinical Stage I, II and IIIA Non-small Cell Lung Cancer Completed
  39. Phase 2 Durvalumab Plus Tremelimumab With Concurrent Radiotherapy for Localized Muscle Invasive Bladder Cancer Treated With a Selective Bladder Preservation Approach Completed
  40. Phase 2 Durvalumab and Tremelimumab in Treating Patients With Recurrent Stage IV Lung Cancer Completed
  41. Phase 2 A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma Completed
  42. Phase 2 Tremelimumab and Durvalumab in Combination or Alone in Treating Patients With Recurrent Malignant Glioma Completed
  43. Phase 2 CTLA-4 /PD-L1 Blockade Following Transarterial Chemoembolization (DEB-TACE) in Patients With Intermediate Stage of HCC (Hepatocellular Carcinoma) Using Durvalumab and Tremelimumab Completed
  44. Phase 2 An Efficacy and Safety Study of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Adults With Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly Patients With Acute Myeloid Leukemia (AML) Completed

Showing the 50 most-cited and recently-updated of 74 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Meta-analysis of neoadjuvant anti-PD-1/PD-L1 plus chemotherapy in resectable NSCLC reports resection and response rates
Oncology Meta-analysis
Meta-analysis of neoadjuvant anti-PD-1/PD-L1 plus chemotherapy in resectable NSCLC reports resection and response rates Combining checkpoint inhibitors with chemotherapy helps more lung cancer patients get surgery safely
This meta-analysis synthesized outcomes from 1,885 patients with potentially resectable non-small cell lung cancer who received neoadjuvant …
A review of 1,885 patients found that adding immune therapy to standard chemo before surgery helped many get clean operations. About one in …
Frontiers May 7, 2026
Meta-analysis shows improved survival with PD-1/PD-L1 inhibitor plus bevacizumab versus sorafenib in advanced HCC
Oncology Meta-analysis
Meta-analysis shows improved survival with PD-1/PD-L1 inhibitor plus bevacizumab versus sorafenib in advanced HCC New Drug Combo Outperforms Standard Care for Liver Cancer
This meta-analysis evaluated PD-1/PD-L1 inhibitor plus bevacizumab versus sorafenib in treatment-naive individuals with advanced hepatocellu…
A powerful two-drug combination cuts the risk of death by 35 percent compared to the standard treatment for people with advanced liver cance…
May 5, 2026
Review of ovarian cancer treatments including olaparib, bevacizumab, and durvalumab discusses limitations and biomarkers
Allergy & Immunology Sys. Review
Review of ovarian cancer treatments including olaparib, bevacizumab, and durvalumab discusses limitations and biomarkers New drug combos target hidden cancer switches to stop resistance
This narrative review examines ovarian cancer management involving olaparib, bevacizumab, and durvalumab.
Hidden chemical changes in ovarian cancer cells help them hide from drugs, but new combinations might finally stop them from adapting and gr…
Frontiers May 1, 2026
Network meta-analysis of anti-PD-1/PD-L1 regimens in advanced non-squamous NSCLC without EGFR or ALK alterations
Pulmonology & Critical Care Meta-analysis
Network meta-analysis of anti-PD-1/PD-L1 regimens in advanced non-squamous NSCLC without EGFR or ALK alterations New drugs beat old ones for advanced lung cancer survival
This systematic review and network meta-analysis evaluated overall survival and progression-free survival across 15 Phase III randomized cli…
New drug combinations show better survival chances for advanced lung cancer patients whether their tumors express PD-L1 or not
May 1, 2026
Systematic review and meta-analysis compares subcutaneous versus intravenous PD-1/PD-L1 inhibitors for solid tumors
Oncology Meta-analysis
Systematic review and meta-analysis compares subcutaneous versus intravenous PD-1/PD-L1 inhibitors for solid tumors Subcutaneous shots match intravenous drugs for cancer survival and response rates in solid tumors
This systematic review and meta-analysis of 1243 patients with solid tumors found no significant difference in overall survival, progression…
A large review found that giving cancer drugs under the skin works just as well as the traditional vein injection for patients with solid tu…
Frontiers Apr 27, 2026
Five medications including daptomycin and durvalumab show positive association with drug-induced eosinophilic pneumonia in database analysis
Rheumatology Cohort
Five medications including daptomycin and durvalumab show positive association with drug-induced eosinophilic pneumonia in database analysis 15,000 Cases Found: Which Drugs Harm Your Lungs?
A retrospective pharmacovigilance investigation analyzed 15,374 cases in FAERS and Vigibase databases to identify drug-induced eosinophilic …
A massive data review reveals which medicines might silently damage your lungs.
Frontiers Apr 22, 2026
Savolitinib and durvalumab combination yields response rates of 34% to 53% in papillary renal cancer patients
Oncology Phase II
Savolitinib and durvalumab combination yields response rates of 34% to 53% in papillary renal cancer patients New Hope for a Tough Kidney Cancer Type
This single-arm phase II study evaluated savolitinib and durvalumab in 41 treatment-naïve or pretreated patients with papillary renal cancer…
A new drug pair breaks the shield blocking treatment for a rare kidney cancer type, offering patients a chance at longer survival after stan…
Apr 20, 2026
Narrative review discusses immune checkpoint inhibitors in lung cancer patients
Allergy & Immunology Sys. Review
Narrative review discusses immune checkpoint inhibitors in lung cancer patients New Hope for Lung Cancer Patients
This narrative review examines immune checkpoint inhibitors (ICIs), including PD-1/PD-L1 and CTLA-4 inhibitors, for patients with lung cance…
Lung cancer patients now have a fighting chance as new medicines help the body's own immune system attack tumors instead of just killing cel…
Frontiers Apr 20, 2026
Salvage radiotherapy for limited metastatic relapse in small cell lung cancer after durvalumab
Oncology Cohort
Salvage radiotherapy for limited metastatic relapse in small cell lung cancer after durvalumab Two patients with limited-stage small cell lung cancer had durable disease control after salvage radiotherapy and immunotherapy
This case report describes two patients with limited-stage small cell lung cancer who developed limited metastatic relapse after chemoradiot…
Two limited-stage small cell lung cancer patients stayed stable for over four years after targeted radiation and continued immunotherapy.
Frontiers Apr 17, 2026
Durvalumab plus chemotherapy improves event-free and overall survival in muscle-invasive bladder cancer compared to chemotherapy alone
Oncology RCT
Durvalumab plus chemotherapy improves event-free and overall survival in muscle-invasive bladder cancer compared to chemotherapy alone New treatment approach improves survival for advanced bladder cancer patients before surgery
This randomized, phase III, open-label trial evaluated neoadjuvant and adjuvant durvalumab combined with gemcitabine and cisplatin versus ge…
Adding an immune drug to standard chemotherapy before bladder surgery helps patients stay cancer-free longer and live longer than older trea…
Apr 16, 2026
SBRT plus PD-1 inhibitor and lenvatinib improved PFS in oligoprogressive HCC patients
Gastroenterology Phase II
SBRT plus PD-1 inhibitor and lenvatinib improved PFS in oligoprogressive HCC patients Radiation Plus Immune Drugs Stops Liver Cancer Growth
This prospective Phase 2 study evaluated stereotactic body radiation therapy (SBRT) combined with continued first-line PD-1 inhibitor-based …
Combining targeted radiation with ongoing immune therapy can restart cancer control in patients whose disease was slowly spreading again.
Apr 12, 2026
Olaparib plus durvalumab showed activity in mCRPC patients previously treated with abiraterone or enzalutamide
Oncology Phase II
Olaparib plus durvalumab showed activity in mCRPC patients previously treated with abiraterone or enzalutamide Two Cancer Drugs Teamed Up — Who Actually Benefits Most?
This single-arm, open-label phase 2 trial evaluated olaparib plus durvalumab in 60 men with metastatic castration-resistant prostate cancer …
A new prostate cancer drug combo helped men with specific DNA repair gene variants live more than twice as long without their cancer progres…
Apr 10, 2026

All durvalumab Articles